Trevi Therapeutics (NASDAQ:TRVI – Get Rating) had its price target raised by Oppenheimer to $12.00 in a research report sent to investors on Monday, Stock Target Advisor reports.
Several other brokerages have also recently weighed in on TRVI. Aegis assumed coverage on Trevi Therapeutics in a research note on Tuesday, March 29th. They set a buy rating and a $10.00 price objective on the stock. Needham & Company LLC raised their price objective on Trevi Therapeutics from $8.00 to $10.00 and gave the company a buy rating in a research note on Wednesday, June 29th.Get Trevi Therapeutics alerts:
Shares of TRVI opened at $3.79 on Monday. Trevi Therapeutics has a 12-month low of $0.46 and a 12-month high of $3.86. The business's fifty day moving average is $2.40 and its 200 day moving average is $1.74. The company has a quick ratio of 2.32, a current ratio of 2.32 and a debt-to-equity ratio of 0.67. The stock has a market cap of $146.64 million, a P/E ratio of -2.81 and a beta of 0.18.Trevi Therapeutics (NASDAQ:TRVI – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.07. During the same period in the prior year, the firm earned ($0.43) earnings per share. On average, analysts expect that Trevi Therapeutics will post -0.81 EPS for the current year.
In other news, major shareholder Paul Edward Walker acquired 3,580,526 shares of the firm's stock in a transaction that occurred on Monday, April 11th. The stock was bought at an average price of $1.90 per share, with a total value of $6,802,999.40. Following the acquisition, the insider now owns 10,421,428 shares in the company, valued at approximately $19,800,713.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Tpg Gp A, Llc sold 436,431 shares of Trevi Therapeutics stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $2.86, for a total value of $1,248,192.66. Following the transaction, the insider now directly owns 3,888,452 shares of the company's stock, valued at approximately $11,120,972.72. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 553,999 shares of company stock valued at $1,594,044. Insiders own 47.30% of the company's stock.
A number of hedge funds have recently bought and sold shares of TRVI. Commonwealth Equity Services LLC purchased a new position in Trevi Therapeutics during the 1st quarter valued at about $33,000. WealthTrust Axiom LLC boosted its position in shares of Trevi Therapeutics by 245.6% during the 1st quarter. WealthTrust Axiom LLC now owns 98,500 shares of the company's stock valued at $216,000 after acquiring an additional 70,000 shares during the last quarter. MAI Capital Management bought a new stake in shares of Trevi Therapeutics during the 1st quarter valued at about $3,391,000. Vanguard Group Inc. boosted its position in shares of Trevi Therapeutics by 7.6% during the 1st quarter. Vanguard Group Inc. now owns 152,831 shares of the company's stock valued at $336,000 after acquiring an additional 10,780 shares during the last quarter. Finally, State Street Corp bought a new stake in shares of Trevi Therapeutics during the 1st quarter valued at about $81,000. 75.34% of the stock is owned by institutional investors and hedge funds.
About Trevi Therapeutics (Get Rating)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.
- Get a free copy of the StockNews.com research report on Trevi Therapeutics (TRVI)
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Credo Technology Stock is Rebounding
- Investing In Preferred Stock vs. Common Stock
- Profiting From 52 Week Low Stocks
- Three Cheap Stocks The Insiders Are Buying
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.